Keros Therapeutics, Inc. (KROS) NASDAQ

20.20

+2.1011(+11.61%)

Updated at December 04 03:24PM

Currency In USD

Valuation

Market Cap592.64M
Enterprise Value51.57M
P/E Ratio11.77
PEG Ratio0.03
Price/Sales Ratio3.07
Price/Book Ratio1.08
Enterprise/Revenue0.33
Enterprise/EBITDA1.07

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin0.26
Operating Margin0.18

Management Effectiveness

Return On Assets0.09
Return On Equity0.1

Income Statement

Revenue3.55M
Revenue/Share6.07
Gross Profit3.55M
EBITDA-185.82M
Net Income-187.35M
Diluted EPS-5

Balance Sheet

Total Cash693.47M
Total Cash/Share17.07
Total Debt17.43M
Total Debt/Equity0.02
Current Ratio29.86
Book Value Per Share17.32

Price History

52-Week Change-72.46
52-Week High72.37
52-Week Low9.12
Moving Average 50 Days16.04
Moving Average 200 Days14.15

Statistics

Average Volume940,066
Shares Outstanding40.54M
% Held by Institutions86.91

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A